Medlive Technology Co., Ltd.
Simbolis: 2192.HK
HKSE
8.51
HKDRinkos kaina šiandien
23.3856
P/E santykis
-0.5721
PEG koeficientas
6.19B
MRK kapitalizacija
- 0.02%
DIV pajamingumas
Medlive Technology Co., Ltd. (2192-HK) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 17632.85 | 4400.9 | 4216.9 | 3908.7 | ||||||
balance-sheet.row.short-term-investments | 127.15 | 42.6 | 29.6 | 29.6 | ||||||
balance-sheet.row.net-receivables | 581.29 | 155.9 | 124.2 | 95.9 | ||||||
balance-sheet.row.inventory | 0.62 | 0.1 | 0.2 | 0.1 | ||||||
balance-sheet.row.other-current-assets | 229.63 | 58.3 | 35.4 | 33 | ||||||
balance-sheet.row.total-current-assets | 18279.8 | 4572.6 | 4351.7 | 4013 | ||||||
balance-sheet.row.property-plant-equipment-net | 45.37 | 11.1 | 14.6 | 16.9 | ||||||
balance-sheet.row.goodwill | 726.41 | 192.5 | 111.5 | 69.7 | ||||||
balance-sheet.row.intangible-assets | 152.99 | 66.7 | 24.3 | 9.3 | ||||||
balance-sheet.row.goodwill-and-intangible-assets | 879.4 | 259.3 | 135.9 | 79 | ||||||
balance-sheet.row.long-term-investments | 233.75 | 42.4 | 63.2 | -29.3 | ||||||
balance-sheet.row.tax-assets | 17.98 | 8.5 | 8.3 | 6.3 | ||||||
balance-sheet.row.other-non-current-assets | 96.83 | 0 | 29.6 | 29.6 | ||||||
balance-sheet.row.total-non-current-assets | 1273.32 | 321.2 | 251.5 | 102.6 | ||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.total-assets | 19553.12 | 4893.8 | 4603.2 | 4115.6 | ||||||
balance-sheet.row.account-payables | 36.9 | 14.8 | 2.7 | 6.2 | ||||||
balance-sheet.row.short-term-debt | 8.87 | 4.5 | 5.1 | 4.2 | ||||||
balance-sheet.row.tax-payables | 46.5 | 25.7 | 35.2 | 31.6 | ||||||
balance-sheet.row.long-term-debt-total | 15.72 | 3.6 | 6.1 | 9 | ||||||
Deferred Revenue Non Current | -7.54 | -7.5 | 0 | 0 | ||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 10.66 | - | - | - | ||||||
balance-sheet.row.other-current-liab | 770 | 175 | 124.9 | 102.8 | ||||||
balance-sheet.row.total-non-current-liabilities | 168.82 | 58.8 | 38.6 | 30.2 | ||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.capital-lease-obligations | 33.45 | 8.2 | 11.3 | 13.2 | ||||||
balance-sheet.row.total-liab | 980.04 | 248.6 | 171.3 | 143.4 | ||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 39 | ||||||
balance-sheet.row.common-stock | 0.18 | 0 | 0 | 0 | ||||||
balance-sheet.row.retained-earnings | 1070.8 | 284.9 | 175.3 | 75.6 | ||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 5901.59 | 4597.3 | 308.1 | -39 | ||||||
balance-sheet.row.other-total-stockholders-equity | 11434.72 | -284.9 | 3917.6 | 3873 | ||||||
balance-sheet.row.total-stockholders-equity | 18407.29 | 4597.4 | 4401 | 3948.7 | ||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 19553.12 | 4893.8 | 4603.2 | 4115.6 | ||||||
balance-sheet.row.minority-interest | 165.8 | 47.8 | 30.9 | 23.5 | ||||||
balance-sheet.row.total-equity | 18573.09 | 4645.2 | 4431.9 | 3972.2 | ||||||
balance-sheet.row.total-liabilities-and-total-equity | 19553.12 | - | - | - | ||||||
Total Investments | 318.26 | 42.4 | 92.8 | 0.3 | ||||||
balance-sheet.row.total-debt | 24.58 | 8.2 | 11.3 | 13.2 | ||||||
balance-sheet.row.net-debt | -17438.47 | -4350.1 | -4176 | -3865.9 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 242.3 | 242.3 | 135 | 69.9 | ||||||
cash-flows.row.depreciation-and-amortization | 9.21 | 0 | 9 | 6.1 | ||||||
cash-flows.row.deferred-income-tax | -19.3 | 0 | 0 | -13.7 | ||||||
cash-flows.row.stock-based-compensation | 10.41 | 10.4 | 17.2 | 14.3 | ||||||
cash-flows.row.change-in-working-capital | 15.77 | 0 | -9.6 | -27.9 | ||||||
cash-flows.row.account-receivables | -16.32 | 0 | -25.1 | -31.7 | ||||||
cash-flows.row.inventory | 0.1 | 0 | -0.1 | -0.1 | ||||||
cash-flows.row.account-payables | 0.17 | 0 | 25.1 | 31.7 | ||||||
cash-flows.row.other-working-capital | 31.98 | 0 | -9.5 | -27.8 | ||||||
cash-flows.row.other-non-cash-items | -175.83 | -252.7 | -74.5 | -4.4 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 101.87 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.75 | 0 | -7.5 | -2 | ||||||
cash-flows.row.acquisitions-net | -56.39 | 0 | -42.6 | -53 | ||||||
cash-flows.row.purchases-of-investments | -5.65 | 0 | -3579.7 | -5.3 | ||||||
cash-flows.row.sales-maturities-of-investments | 1.58 | 0 | 0.7 | 5.3 | ||||||
cash-flows.row.other-investing-activites | -577.8 | 0 | 43.5 | 4.4 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | -634.95 | 0 | -3585.6 | -50.5 | ||||||
cash-flows.row.debt-repayment | 0 | 0 | -5 | -6.5 | ||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 4033.1 | ||||||
cash-flows.row.common-stock-repurchased | -0.68 | 0 | 5 | 0 | ||||||
cash-flows.row.dividends-paid | -124.69 | 0 | -12.1 | -92 | ||||||
cash-flows.row.other-financing-activites | -7.76 | 0 | -10.2 | -142.6 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -133.13 | 0 | -22.4 | 3792.1 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | 63.06 | 0 | 329.9 | -53.9 | ||||||
cash-flows.row.net-change-in-cash | 1308.37 | 0 | -3200.9 | 3732 | ||||||
cash-flows.row.cash-at-end-of-period | 6009.58 | 678.2 | 678.2 | 3879.1 | ||||||
cash-flows.row.cash-at-beginning-of-period | 4701.21 | 678.2 | 3879.1 | 147.1 | ||||||
cash-flows.row.operating-cash-flow | 101.87 | 0 | 77.2 | 44.4 | ||||||
cash-flows.row.capital-expenditure | -0.75 | 0 | -7.5 | -2 | ||||||
cash-flows.row.free-cash-flow | 101.12 | 0 | 69.7 | 42.5 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 412 | 412 | 314.1 | 284.4 | ||||||
income-statement-row.row.cost-of-revenue | 160.67 | 160.7 | 101.3 | 83.7 | ||||||
income-statement-row.row.gross-profit | 251.34 | 251.3 | 212.7 | 200.7 | ||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.research-development | 54.26 | - | - | - | ||||||
income-statement-row.row.selling-general-administrative | 141.3 | - | - | - | ||||||
income-statement-row.row.selling-and-marketing-expenses | 32.78 | - | - | - | ||||||
income-statement-row.row.other-expenses | 0 | -8.9 | -8 | -0.7 | ||||||
income-statement-row.row.operating-expenses | 182.51 | 173.6 | 143.4 | 126.9 | ||||||
income-statement-row.row.cost-and-expenses | 343.18 | 334.2 | 244.7 | 210.7 | ||||||
income-statement-row.row.interest-income | 184.31 | 183.9 | 66.2 | 7.7 | ||||||
income-statement-row.row.interest-expense | 0.22 | 0.4 | 0.5 | 0.5 | ||||||
income-statement-row.row.selling-and-marketing-expenses | 32.78 | - | - | - | ||||||
income-statement-row.row.total-other-income-expensenet | 188 | 188.1 | 0.2 | -0.4 | ||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||
income-statement-row.row.other-operating-expenses | 0 | -8.9 | -8 | -0.7 | ||||||
income-statement-row.row.total-operating-expenses | 188 | 188.1 | 0.2 | -0.4 | ||||||
income-statement-row.row.interest-expense | 0.22 | 0.4 | 0.5 | 0.5 | ||||||
income-statement-row.row.depreciation-and-amortization | 3.91 | 9.4 | 9 | 6.1 | ||||||
income-statement-row.row.ebitda-caps | 69.05 | - | - | - | ||||||
income-statement-row.row.operating-income | 65.14 | 65 | 134.8 | 70.3 | ||||||
income-statement-row.row.income-before-tax | 253.13 | 253.1 | 135 | 69.9 | ||||||
income-statement-row.row.income-tax-expense | 1.37 | 1.4 | 8.6 | 24.7 | ||||||
income-statement-row.row.net-income | 242.3 | 242.3 | 117.3 | 40.6 |
Dažnai užduodami klausimai
Kas yra Medlive Technology Co., Ltd. (2192.HK) bendras turtas?
Medlive Technology Co., Ltd. (2192.HK) bendras turtas yra 4893816000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 238498000.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.610.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 0.138.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.588.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.158.
Kas yra Medlive Technology Co., Ltd. (2192.HK) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 242301000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 8192000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 173579000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 4358255000.000.